TFDA-2024-0091-V391
Type IB variation for application TFDA-2024-0091. Type IB variation: Facility Change for Kcluximab — critical change
Variation Number
TFDA-2024-0091-V391
Type
Type IB
Application
Change
Status
Completed
Fee
€2,437
Submitted
2024-04-15
Approved
—
Description
Type IB variation: Facility Change for Kcluximab — critical change